Stocktoria
Jiangsu Hengrui Pharmaceuticals Co.,Ltd 600276.SS
Jiangsu Hengrui Pharmaceuticals Co.,Ltd (600276.SS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.36% (safety: safe). FY2025 revenue was $31.6B at a 24.4% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 36 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.646 |
| Retained earnings / assets | 0.575 |
| EBIT / assets | 0.123 |
| Equity / liabilities | 7.592 |
FAQ
Is 600276.SS financially healthy?
Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does 600276.SS pay a dividend, and is it safe?
Yes. Jiangsu Hengrui Pharmaceuticals Co.,Ltd pays a dividend yielding about 0.36% with a 16.7% payout ratio, rated “safe” for safety.
How profitable is 600276.SS?
In FY2025, Jiangsu Hengrui Pharmaceuticals Co.,Ltd had a net margin of 24.4% and a return on equity of 12.6%.
Source: company filings via Yahoo Finance · CN · as of 2025-12-31. Figures in CNY; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.